Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2/3 3Phase 2 2Phase 4 1Phase 1/2 1Phase 1 1

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Neoplasms 3Colonic Neoplasms 3Breast Neoplasms 3Pain 2Leiomyoma 2Wounds and Injuries 1Stomatitis 1Postoperative Hemorrhage 1Mucositis 1Malignant Pleural Neoplasm 1Inflammatory Bowel Diseases 1Ileus 1Head and Neck Neoplasms 1Feeding and Eating Disorders 1Diverticulitis 1Colorectal Neoplasms 1Cancer Pain 1Agnosia 1

Interventions

Morphine 6Analgesia 6nabiximols 3Pregabalin 3Oxycodone 3Fentanyl 3ziconotide 2Surveys and Questionnaires 2Saline Solution 2Radiofrequency Ablation 2Methadone 2Lidocaine 2Ketamine 2Ibandronic Acid 2Gemcitabine 2Duloxetine Hydrochloride 2Docetaxel 2Botulinum Toxins, Type A 2trimebutine 3-thiocarbamoylbenzenesulfonate 1tanezumab 1tandutinib 1siltuximab 1resiniferatoxin 1incobotulinumtoxinA 1imisopasem manganese 1fulranumab 1erenumab 1cyclobenzaprine 1caffeine, sodium benzoate drug combination 1Therapeutics 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Pain × Lidocaine × Clear all
NCT04250805 2024-01-31

GASTROXY

Centre Hospitalier Universitaire de Saint Etienne

Phase 2 Terminated
17 enrolled

Feeding and Eating Disorders, Neoplasms, Pain

NCT00321347 2012-06-22

Intravenous (IV) Lidocaine for Opioid-refractory Pain

San Diego Hospice & Palliative Care

Phase 2 Withdrawn

Neoplasms, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡